Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 6

Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of cataracts and glaucoma among chronic obstructive pulmonary disease patients in the UK General Practice Research Database

Authors Miller DP, Watkins SE, Sampson T, Davis KJ

Published Date September 2011 Volume 2011:6 Pages 467—476

DOI http://dx.doi.org/10.2147/COPD.S14247

Published 16 September 2011

David P Miller, Stephanie E Watkins, Tim Sampson, Kourtney J Davis
WorldWide Epidemiology, GlaxoSmithKline, Durham, NC, USA

Objectives: Some large population-based studies have reported a dose-related increased risk of cataracts and glaucoma associated with use of inhaled corticosteroids (ICS) in patients with asthma or chronic obstructive pulmonary disease (COPD). We evaluated the association between use of ICS-containing products, specifically fluticasone propionate/salmeterol fixed-dose combination (FSC), and incidence of cataracts and glaucoma among patients with COPD in a large electronic medical record database in the United Kingdom.
Methods: We identified a cohort of patients aged 45 years and over with COPD in the General Practice Research Database (GPRD) between 2003 and 2006. Cases of incident cataracts or glaucoma were defined based on diagnosis and procedure codes and matched to controls from the risk set to estimate odds ratios (OR) and 95% confidence intervals (CI). The association with FSC or ICS exposure was modeled using conditional logistic regression. Medication exposure was assessed with respect to recency, duration, and number of prescriptions prior to the index date. Average daily dose was defined as none, low (1–250 mcg), medium (251–500 mcg), high (501–1000 mcg), or very high (1001+ mcg) using fluticasone propionate (FP) equivalents.
Results: We identified 2941 incident cataract cases and 327 incident glaucoma cases in the COPD cohort (n = 53,191). FSC or ICS prescriptions were not associated with risk of incident cataracts or glaucoma for any exposure category, after adjusting for confounders. We observed a lack of a dose response in all analyses, where low dose was the reference group. The odds of cataracts associated with FSC dose were medium OR: 1.1 (95% CI: 0.9–1.4); high OR: 1.2 (95% CI: 0.9–1.5); and very high OR: 1.2 (95% CI: 0.9–1.7). The odds of glaucoma associated with FSC dose: medium OR: 1.0 (95% CI: 0.5–2.1); high OR: 1.0 (95% CI: 0.5–2.0); and very high OR: 1.0 (95% CI: 0.4–2.8).
Conclusions: FSC or other ICS exposure was not associated with an increased odds of cataracts or glaucoma, nor was a dose–response relationship observed in this population-based nested case-control study of COPD patients in the United Kingdom.

Keywords: inhaled corticosteroids, fluticasone ropionate/salmeterol, cataracts, glaucoma, risk

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Nutritional deficits in elderly smokers with respiratory symptoms that do not fulfill the criteria for COPD

Obase Y, Mouri K, Shimizu H, Ohue Y, Kobashi Y, Kawahara K, Oka M

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:679-683

Published Date: 9 December 2011

Cognitive behavioral therapy for insomnia comorbid with COPD is feasible with preliminary evidence of positive sleep and fatigue effects

Kapella MC, Herdegen JJ, Perlis ML, Shaver JL, Larson JL, Law JA, Carley DW

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:625-635

Published Date: 24 November 2011

The effects of long-term noninvasive ventilation in hypercapnic COPD patients: a randomized controlled pilot study

De Backer L, Vos W, Dieriks B, Daems D, Verhulst S, Vinchurkar S, Ides K, De Backer J, Germonpre P, De Backer W

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:615-624

Published Date: 18 November 2011

Asthma, chronic obstructive pulmonary disease, or both? Diagnostic labeling and spirometry in primary care patients aged 40 years or more

Melbye H, Drivenes E, Dalbak LG, Leinan T, Høegh-Henrichsen S, Østrem A

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:597-603

Published Date: 17 November 2011

Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims

Mapel DW, Dalal AA, Blanchette CM, Petersen H, Ferguson GT

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:573-581

Published Date: 9 November 2011

Predictive properties of different multidimensional staging systems in patients with chronic obstructive pulmonary disease

Oga T, Tsukino M, Hajiro T, Ikeda A, Nishimura K

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:521-526

Published Date: 11 October 2011

Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients

Tzani P, Crisafulli E, Nicolini G, Aiello M, Chetta A, Clini E, Olivieri D

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:503-509

Published Date: 4 October 2011